Department of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Shapingba District, Chongqing, China.
Department of Neurology, The 903rd Hospital of The Chinese People's Liberation Army, Xihu District, Hangzhou, China.
JAMA. 2021 Jan 19;325(3):234-243. doi: 10.1001/jama.2020.23523.
For patients with large vessel occlusion strokes, it is unknown whether endovascular treatment alone compared with intravenous thrombolysis plus endovascular treatment (standard treatment) can achieve similar functional outcomes.
To investigate whether endovascular thrombectomy alone is noninferior to intravenous alteplase followed by endovascular thrombectomy for achieving functional independence at 90 days among patients with large vessel occlusion stroke.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, noninferiority trial conducted at 33 stroke centers in China. Patients (n = 234) were 18 years or older with proximal anterior circulation intracranial occlusion strokes within 4.5 hours from symptoms onset and eligible for intravenous thrombolysis. Enrollment took place from May 20, 2018, to May 2, 2020. Patients were enrolled and followed up for 90 days (final follow-up was July 22, 2020).
A total of 116 patients were randomized to the endovascular thrombectomy alone group and 118 patients to combined intravenous thrombolysis and endovascular thrombectomy group.
The primary end point was the proportion of patients achieving functional independence at 90 days (defined as score 0-2 on the modified Rankin Scale; range, 0 [no symptoms] to 6 [death]). The noninferiority margin was -10%. Safety outcomes included the incidence of symptomatic intracerebral hemorrhage within 48 hours and 90-day mortality.
The trial was stopped early because of efficacy when 234 of a planned 970 patients had undergone randomization. All 234 patients who were randomized (mean age, 68 years; 102 women [43.6%]) completed the trial. At the 90-day follow-up, 63 patients (54.3%) in the endovascular thrombectomy alone group vs 55 (46.6%) in the combined treatment group achieved functional independence at the 90-day follow-up (difference, 7.7%, 1-sided 97.5% CI, -5.1% to ∞)P for noninferiority = .003). No significant between-group differences were detected in symptomatic intracerebral hemorrhage (6.1% vs 6.8%; difference, -0.8%; 95% CI, -7.1% to 5.6%) and 90-day mortality (17.2% vs 17.8%; difference, -0.5%; 95% CI, -10.3% to 9.2%).
Among patients with ischemic stroke due to proximal anterior circulation occlusion within 4.5 hours from onset, endovascular treatment alone, compared with intravenous alteplase plus endovascular treatment, met the prespecified statistical threshold for noninferiority for the outcome of 90-day functional independence. These findings should be interpreted in the context of the clinical acceptability of the selected noninferiority threshold.
Chinese Clinical Trial Registry: ChiCTR-IOR-17013568.
对于大血管闭塞性中风患者,尚不清楚单独进行血管内治疗是否与静脉溶栓联合血管内治疗(标准治疗)相比,能够达到相似的功能结局。
研究单纯血管内血栓切除术是否不劣于静脉阿替普酶溶栓后联合血管内血栓切除术,以实现大血管闭塞性中风患者 90 天的功能独立。
设计、地点和参与者:在中国 33 家中风中心进行的多中心、随机、非劣效性试验。患者(n=234)年龄在 18 岁或以上,症状发作后 4.5 小时内存在近端前循环颅内闭塞性中风,且符合静脉溶栓条件。入组时间为 2018 年 5 月 22 日至 2020 年 5 月 2 日。患者入组并随访 90 天(最终随访时间为 2020 年 7 月 22 日)。
共有 116 例患者随机分配至单纯血管内血栓切除术组,118 例患者随机分配至静脉溶栓联合血管内血栓切除术组。
主要结局是 90 天功能独立的患者比例(定义为改良 Rankin 量表评分为 0-2 分;范围为 0 [无症状]至 6 [死亡])。非劣效性边界为-10%。安全性结局包括 48 小时内症状性颅内出血和 90 天死亡率。
在计划入组的 970 例患者中,有 234 例患者进行了随机分组,该试验提前停止,因为疗效显著。所有 234 例随机分组的患者(平均年龄 68 岁;102 例女性[43.6%])均完成了试验。在 90 天随访时,单纯血管内血栓切除术组 63 例(54.3%)患者与联合治疗组 55 例(46.6%)患者在 90 天随访时达到功能独立(差异为 7.7%,单侧 97.5%CI,-5.1%至∞;P 非劣效性=0.003)。两组在症状性颅内出血(6.1% vs 6.8%;差异,-0.8%;95%CI,-7.1%至 5.6%)和 90 天死亡率(17.2% vs 17.8%;差异,-0.5%;95%CI,-10.3%至 9.2%)方面无显著差异。
对于发病 4.5 小时内的近端前循环闭塞性中风患者,与静脉阿替普酶溶栓联合血管内治疗相比,单独血管内治疗在 90 天功能独立结局方面达到了预设的统计学非劣效性阈值。这些发现应结合所选非劣效性阈值的临床可接受性来解释。
中国临床试验注册中心:ChiCTR-IOR-17013568。